Nutriband Inc. reported record revenue of $667,000 USD for the first quarter ended April 30, 2025, marking a 63% increase year-over-year. This significant growth was primarily driven by its Pocono Pharma subsidiary, which continues to expand its kinesiology tape output.
Pocono manufactured products are rolling out into prominent retail locations nationwide, including Target, Walmart, Walgreens, and CVS, contributing to the company's revenue stream. This operational success provides a stable foundation while the pharmaceutical pipeline matures.
Progress on AVERSA Fentanyl development continued, with the company formalizing an exclusive product development partnership with Kindeva Drug Delivery. AVERSA Fentanyl has the potential to become the world’s first abuse-deterrent opioid patch and is estimated to reach peak annual US sales of $80 million to $200 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.